Trends in Mid-sized European Licensing
Mid-sized European drug firms have traditionally spent considerably more on in-licensing than they've received from licensing out their products to other partners. But over the past two years, we've detected a dramatic shift in the ratio of dollars spent versus received in alliances.
You may also be interested in...
On balance, do mid-sized European players receive more licensing dollars from out-licensing than they spend on in-licensing?
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.